Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
USE OF ASPIRIN AND OTHER NONSTEROIDAL ANTIINFLAMMATORY DRUGS AND RISKOF ESOPHAGEAL AND GASTRIC-CANCER
Autore:
FARROW DC; VAUGHAN TL; HANSTEN PD; STANFORD JL; RISCH HA; GAMMON MD; CHOW WH; DUBROW R; AHSAN H; MAYNE ST; SCHOENBERG JB; WEST AB; ROTTERDAM H; FRAUMENI JF; BLOT WJ;
Indirizzi:
FRED HUTCHINSON CANC RES CTR,PROGRAM EPIDEMIOL,1100 FAIRVIEW AVE N,POB 19024,MP-474 SEATTLE WA 98104 UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT EPIDEMIOL SEATTLE WA 98195 UNIV WASHINGTON,DEPT PHARM SEATTLE WA 98195 YALE UNIV,SCH MED,DEPT EPIDEMIOL & PUBL HLTH NEW HAVEN CT 06510 YALE UNIV,SCH MED,DEPT PATHOL NEW HAVEN CT 06510 COLUMBIA SCH PUBL HLTH,DIV EPIDEMIOL NEW YORK NY 10032 NCI,DIV CANC EPIDEMIOL & GENET BETHESDA MD 20852 NEW JERSEY DEPT HLTH & SENIOR SERV,OFF CANC EPIDEMIOL TRENTON NJ 08625 COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL NEW YORK NY 10032 INT EPIDEMIOL INST ROCKVILLE MD 20850
Titolo Testata:
Cancer epidemiology, biomarkers & prevention
fascicolo: 2, volume: 7, anno: 1998,
pagine: 97 - 102
SICI:
1055-9965(1998)7:2<97:UOAAON>2.0.ZU;2-V
Fonte:
ISI
Lingua:
ENG
Soggetto:
COLORECTAL-CANCER; ANTIINFLAMMATORY DRUGS; BREAST-CANCER; REDUCED RISK; COLON CANCER; LARGE-BOWEL; ADENOCARCINOMA; CARCINOMA; TOBACCO; ALCOHOL;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
31
Recensione:
Indirizzi per estratti:
Citazione:
D.C. Farrow et al., "USE OF ASPIRIN AND OTHER NONSTEROIDAL ANTIINFLAMMATORY DRUGS AND RISKOF ESOPHAGEAL AND GASTRIC-CANCER", Cancer epidemiology, biomarkers & prevention, 7(2), 1998, pp. 97-102

Abstract

Regular users of aspirin and other nonsteroidal antiinflammatory drugs (NSAIDs) are at reduced risk of colon cancer, but the evidence for protective effects of NSAIDs elsewhere in the digestive tract is scant. We investigated the association between the use of NSAIDs and risk ofesophageal and gastric cancer, using data from a large population-based, case-control study. Cases were individuals, ages 30-79 years, diagnosed with esophageal adenocarcinoma (n = 293), esophageal squamous cell carcinoma (n = 221), gastric cardia adenocarcinoma (n = 261), or noncardia gastric adenocarcinoma (n = 368) in three areas with population-based tumor registries. Controls (n = 695) were selected by random digit dialing and through the rosters of the Health Care Financing Administration. After controlling for the major risk factors, we found that current users of aspirin were at decreased risk of esophageal adenocarcinoma [odds ratio (OR), 0.37; 95% confidence interval (CI), 0.24-0.58], esophageal squamous cell carcinoma (OR, 0.49; 95% CI, 0.28-0.87),and noncardia gastric adenocarcinoma (OR, 0.46; 95% CI, 0.31-0.68), but not of gastric cardia adenocarcinoma (OR, 0.80; 95% CI, 0.54-1.19),when compared to never users. Risk was similarly reduced among current users of nonaspirin NSAIDs. The associations with current NSAID use persisted when we excluded use within 2 or 5 years of reference date, which might have been affected by preclinical disease in cases, and when we restricted analyses to subjects reporting no history of chronic gastrointestinal symptoms. Our findings add to the growing evidence that the risk of cancers of the esophagus and stomach is reduced in users of NSAIDs, although whether the association is causal in nature is not clear.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/09/20 alle ore 03:40:17